Cardiovascular adverse effects of anti–IL-5/IL-5Rα therapies: A real-world study
Résumé
Omalizumab, an antibody directed against the receptor-binding domain of IgE, was the first biological therapy marketed in severe allergic asthma. Several observational studies including long-term analyses concluded that omalizumab has showed an overall optimal safety profile1-5.Although higher incidence rate of cerebrovascular and cardiovascular adverse events emerged in some studies3, 4, confounding factors between omalizumab and non-omalizumab patients were likely to explain those results. Recently, mepolizumab, reslizumab (both anti-interleukin 5 (IL5)) and benralizumab (an anti-IL5 receptor-α (IL5Rα)) have been associated with a reduction of the exacerbation rate and the dose of oral steroids in eosinophilic severe asthma. In long-term safety studies, rare cardiovascular events such as myocardial infarction, deep venous thrombosis and stroke have been described with benralizumab and mepolizumab. Nevertheless, an association between these events and these drugs is still unknow6, 7. We performed a pharmacovigilance study in order to assess the effect of anti-IL5/IL5Rα therapies on cardiovascular events.
Origine : Fichiers produits par l'(les) auteur(s)